Cummings, Christopher T <br/><br/>
Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer.  [electronic resource] 

 -  Oncotarget  Nov 2014 
 - 10434-45 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.2142  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--pharmacology<br/>Apoptosis--drug effects<br/>Carboplatin--pharmacology<br/>Carcinoma, Non-Small-Cell Lung--immunology<br/>Cell Line, Tumor<br/>Down-Regulation<br/>Drug Resistance--drug effects<br/>Drug Synergism<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Lung Neoplasms--immunology<br/>Mitogen-Activated Protein Kinase 1--metabolism<br/>Mitogen-Activated Protein Kinase 3--metabolism<br/>Molecular Targeted Therapy<br/>Oncogene Protein v-akt--metabolism<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins--genetics<br/>RNA, Small Interfering--genetics<br/>Receptor Protein-Tyrosine Kinases--genetics<br/>STAT6 Transcription Factor--metabolism<br/>Signal Transduction--drug effects<br/>Tumor Stem Cell Assay<br/>c-Mer Tyrosine Kinase